Business
GMP Manufacture Deal With Cobra
GMP Manufacture Deal With Cobra.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \n22/01/2009\n\nGB00B39J5N63\n\n Scancell Holdings Plc \n\n (`Scancell Holdings' or the `Company') \n\n GMP manufacture deal with Cobra Biomanufacturing \n\nScancell Holdings Plc, the parent company of Scancell Limited (`Scancell'), the\ndeveloper of therapeutic cancer vaccines based on its patented ImmunoBodyâ„¢\nplatform, is pleased to announce that it has signed a deal with Cobra\nBiomanufacturing Plc (`Cobra Biomanufacturing') for Good Manufacturing Practice\n(`GMP') manufacture of its SCIB1 DNA vaccine. Scancell plan to commence\nclinical trials of SCIB1 in the UK in 1Q2010.\n\nScancell is developing SCIB1, a DNA vaccine for the potential treatment of\nlate-stage melanoma cancer patients. There are 8000 new cases of melanoma every\nyear in the UK with 1800 deaths per year. Early stage melanoma is often cured\nby surgery but advanced disease has a very poor prognosis with late stage\n(stage IV) disease having a median survival of approximately 6 months. SCIB1\nwas developed using Scancell's ImmunoBodyâ„¢ technology and is engineered to\nexpress the TRP-2 and gp100 cytotoxic T-cell epitopes from tumour antigens. In\nanimal models, SCIB1 prevented the development of lung metastases and\nsignificantly inhibited the growth of established tumours.\n\nCobra Biomanufacturing is an AIM-listed contract manufacturer of\nbiopharmaceuticals that is compliant with cGMP standards worldwide.\n\nDavid Evans, chairman of Scancell, commented:\n\n\"We are delighted to sign a deal with Cobra Biomanufacturing to manufacture our\nSCIB1 DNA vaccine. That we are commencing GMP manufacture of SCIB1 on schedule\nis testament to the progress the Company continues to achieve.\"\n\nSimon Saxby, Chief Executive of Cobra Biomanufacturing said:\n\n\"We are very pleased to be have been selected by Scancell as a result of\nCobra's abilities and reputation as a leading cGMP compliant manufacturer of\nDNA. This agreement also underscores Cobra's long term commitment to the\nmanufacture of therapeutic vaccines.\"\n\nThe Directors of the issuer accept responsibility for this announcement.\n\n -ENDS- \n\nFor Further Information:\n\nProfessor Lindy Durrant Scancell Holdings Plc + 44 207 245 1100 \n \nAdam Reynolds/Vikki Krause Hansard Group + 44 7515 922906 \n \nDuncan Vasey/Barry Hocken St. Helen's Capital Plc + 44 207 628 5582 \n\n\n \n ","length":2803,"tagNa...